Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

Mollee, P., Arthur, C., Hughes, T., Januszewicz, H., Grigg, A., Bradstock, K., Wolf, M., Gibson, J., Schwarer, A. P., Spencer, A., Browett, P., Hawkins, T., Seldon, M., Herrmann, R. and Watson, A. (2004) Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. Annals of Oncology, 15 12: 1810-1815. doi:10.1093/annonc/mdh468

Author Mollee, P.
Arthur, C.
Hughes, T.
Januszewicz, H.
Grigg, A.
Bradstock, K.
Wolf, M.
Gibson, J.
Schwarer, A. P.
Spencer, A.
Browett, P.
Hawkins, T.
Seldon, M.
Herrmann, R.
Watson, A.
Title Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia
Journal name Annals of Oncology   Check publisher's open access policy
ISSN 0923-7534
Publication date 2004
Sub-type Article (original research)
DOI 10.1093/annonc/mdh468
Volume 15
Issue 12
Start page 1810
End page 1815
Total pages 6
Editor D. J. Kerr
Place of publication UK
Publisher Oxford University Press
Collection year 2004
Language eng
Subject C1
321015 Oncology and Carcinogenesis
321008 Haematology
730103 Blood disorders
730108 Cancer and related disorders
Abstract Background: Treatment with interferon and subcutaneous cytarabine produces superior cytogenetic responses in chronic myeloid leukaemia (CML) than treatment with interferon alone, but at the expense of greater toxicity. Cytarabine ocfosfate (YNK01) is an oral precursor of cytarabine that may overcome some of the inconvenience and toxicities associated with subcutaneous cytarabine administration. Patients and methods: We studied the efficacy and tolerability of combination therapy with interferon-alpha-2b and YNK01 in patients with newly diagnosed, untreated CML. Forty patients were treated with interferon-alpha-2b (5 MU/m(2)/day) plus monthly courses of YNK01 (600 mg/day for 10 days) for I year. Results: The 6-month complete haematological response rate was 63% and the 1-year major cytogenetic response rate was 30%, with 10% of cytogenetic responses being complete. With a median follow-up of 57 months, the estimated 5-year overall survival was 86% (95% confidence interval 70% to 94%). Treatment tolerability was poor, with toxicity leading to discontinuation of one or both drugs in 60% of cases. The median daily dose of interferon alpha-2b was 7.75 MU and the median dose of YNK01 was 600 mg/day for each 10-day treatment cycle. Conclusions: Interferon-alpha-2b and YNK01 produce cytogenetic responses comparable to those achieved with interferon-alpha-2b and parenteral cytarabine, although toxicity was excessive. Alternate dosing strategies may enhance the tolerability of YNK01.
Keyword Oncology
Chronic Myeloid Leukaemia
Cytarabine Ocfosfate
Chronic Myelogenous Leukemia
Low-dose Cytarabine
Chemotherapeutic Drugs
Cytogenetic Responses
Arabinosyl Cytosine
Imatinib Mesylate
Q-Index Code C1
Additional Notes Authors of this document: Mollee, P; Arthur, C; Hughes, T; Januszewicz, H; Grigg, A; Bradstock, K; Wolf, M; Gibson, J; Schwarer, AP; Spencer, A; Browett, P; Hawkins, T; Seldon, M; Herrmann, R; Watson, A; Seymour, JF; Martin, N; Shina, S; Low, C; Wright, S; Rodwell, R; Coulston, J; Morton, J; Blacklock, H; Taylor, D; Taylor, KM.

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
2005 Higher Education Research Data Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 5 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 04:06:04 EST